Work

A mutational grouping involving SRSF2, TET2, ASXL1, RUNX1, and STAG2 identifies patients with lower-risk myelodysplastic syndrome who benefit from higher-risk treatment strategies

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-2086

Authors: Brandon Aubrey, Peter Miller, Timothy Graubert, Yi-Bin Chen, Rohiverth Guarecuco, Amir Fathi, Robert Hasserjian, Andrew Brunner

Institutions: Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Brigham and Women's Hospital

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417017086

Cites:

Cited by:

Related to: